TEL-AVIV, Israel, Aug. 11, 2011 /PRNewswire/ -- InspireMD, Inc.  (OTC BB: NSPR) ("Inspire" or the "Company"), the developer of the MGuard™  mesh protective stent system, today announced the election of two proven leaders to the Company's board of directors. Paul S. Stuka, Managing Member of Osiris Partners and a 30-year investment industry veteran, and Eyal Weinstein, a certified public accountant, former executive of several Israeli firms sold to larger companies and a director on the boards of several publicly traded companies, were both elected to InspireMD's Board of Directors. Both will be independent, non-executive directors.
Prior to forming Osiris Partners, Mr. Stuka was a Managing Director of Longwood Partners, managing small cap institutional accounts. In 1995, Mr. Stuka joined State Street Research and Management as manager of its Market Neutral and Mid Cap Growth Funds. From 1986 to 1994, Mr. Stuka served as the general partner of Stuka Associates, where he managed a U.S.-based investment partnership. Mr. Stuka began his career in 1980 as an analyst at Fidelity Management and Research. As an analyst, Mr. Stuka followed a wide array of industries including healthcare, energy, transportation, and lodging & gaming. Early in his career he became the assistant portfolio manager for three Fidelity Funds, including the Select Healthcare Fund, which was recognized as the top performing fund in the U.S. for the five-year period ending December 31, 1985. In 1984 he became the original manager of the Fidelity OTC Fund, which was the second-best performing U.S. mutual fund for 1985, appreciating 69%. At the time of his departure in June, 1986, the Fund had appreciated over 115% in 18 months and assets approached $1 billion. During his career, Mr. Stuka has been featured in articles in The Wall Street Journal, Bar